Dakota15
Senior Member (Voting Rights)
Dec. 2023: 'Fresenius editor Brigitte Baas speaks with Prof. Akiko Iwasaki'
Prof. Iwasaki: 'what we want ultimately: to develop therapies that will help people with long Covid, ME/CFS and other post-acute infection syndromes.'
Prof. Dr. Akiko Iwasaki: 'ME/CFS is a systemic condition manifested mainly by a variety of different neurological and immunological symptoms and accompanied by chronic fatigue not relieved by sleep or rest.'
'Therefore, we are very excited to use the EKFS prize funding, to compare the immune phenotypes between ME/CFS and long Covid head-to-head to understand the similarities and differences even better. '
Prof. Iwasaki: 'Science takes a long time to understand the causes of disease. It will not be weeks or months before we have a handle on long Covid. However, with the efforts of many groups, including ours, we are getting closer and closer to the knowledge we need. In parallel, many clinical trials are beginning to understand empirically which drugs might benefit people with long Covid. It will take a concerted global effort to get there as soon as possible.'
Prof. Iwasaki: 'what we want ultimately: to develop therapies that will help people with long Covid, ME/CFS and other post-acute infection syndromes.'
Prof. Dr. Akiko Iwasaki: 'ME/CFS is a systemic condition manifested mainly by a variety of different neurological and immunological symptoms and accompanied by chronic fatigue not relieved by sleep or rest.'
'Therefore, we are very excited to use the EKFS prize funding, to compare the immune phenotypes between ME/CFS and long Covid head-to-head to understand the similarities and differences even better. '
Prof. Iwasaki: 'Science takes a long time to understand the causes of disease. It will not be weeks or months before we have a handle on long Covid. However, with the efforts of many groups, including ours, we are getting closer and closer to the knowledge we need. In parallel, many clinical trials are beginning to understand empirically which drugs might benefit people with long Covid. It will take a concerted global effort to get there as soon as possible.'